News
CERS
2.610
0.00%
0.000
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis
Seeking Alpha · 4h ago
Cerus management to meet with Craig-Hallum
TipRanks · 3d ago
Cerus COO Vivek K. Jayaraman sells 16,667 shares for $50,001
PUBT · 4d ago
Top 3 Health Care Stocks That May Collapse This Month
Benzinga · 6d ago
Weekly Report: what happened at CERS last week (0427-0501)?
Weekly Report · 6d ago
Cerus Corporation Earnings Call Signals Profitable Growth
TipRanks · 05/02 00:22
Cerus Touches 52-Week High After 1Q Revenue Increases
Dow Jones · 05/01 18:51
Correction to Cerus 1Q Revenue Headline on April 30
Dow Jones · 05/01 18:47
This Caterpillar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Benzinga · 05/01 18:43
Cerus Up Over 26%, On Track for Largest Percent Increase Since August 2009 -- Data Talk
Dow Jones · 05/01 16:25
Midday Fly By: Apple reports Q2 beat, oil majors post mixed results
TipRanks · 05/01 16:06
Cerus upgraded to Buy from Neutral at BTIG
TipRanks · 05/01 12:43
CERUS CORP <CERS.O>: BTIG RAISES TO BUY FROM NEUTRAL
Reuters · 05/01 12:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 05/01 12:05
Cerus Price Target Announced at $4.00/Share by BTIG
Dow Jones · 05/01 11:52
Cerus Raised to Buy From Neutral by BTIG
Dow Jones · 05/01 11:52
BTIG Upgrades Cerus to Buy, Announces $4 Price Target
Benzinga · 05/01 11:42
Cerus outlines raised 2026 product revenue guidance to $227M-$231M driven by platelet and IFC demand
Seeking Alpha · 05/01 08:22
U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco International
Reuters · 05/01 07:29
Cerus (CERS) Q1 2026 Earnings Transcript
NASDAQ · 04/30 23:26
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.